FCGR2A and breast cancer: Further, in a sample of 15 operable and 35 metastatic HER2-positive breast cancer patients, FCGR2A His/His predicted the response to trastuzumab in neoadjuvant chemotherapy and in metastatic setting, while FCGR3A Val/Val did not [13].